Theodore Karrison to Survival Rate
This is a "connection" page, showing publications Theodore Karrison has written about Survival Rate.
Connection Strength
0.368
-
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. Br J Haematol. 2018 04; 181(2):264-267.
Score: 0.107
-
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
Score: 0.034
-
Does pneumonectomy for lung cancer adversely influence long-term survival? J Thorac Cardiovasc Surg. 2000 Mar; 119(3):440-8.
Score: 0.033
-
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302.
Score: 0.030
-
Comparison of median survival times with adjustment for covariates. Stat Med. 1995 Dec 15; 14(23):2537-53.
Score: 0.024
-
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43.
Score: 0.022
-
Quantitative allelic test--a fast test for very large association studies. Genet Epidemiol. 2013 Dec; 37(8):831-9.
Score: 0.021
-
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8.
Score: 0.018
-
Increased all-cause and cardiac morbidity and mortality associated with the diagonal earlobe crease: a prospective cohort study. Am J Med. 1991 Sep; 91(3):247-54.
Score: 0.018
-
Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010 Jun 01; 28(16):2653-9.
Score: 0.016
-
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40.
Score: 0.012
-
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. Invest New Drugs. 2004 Aug; 22(3):323-7.
Score: 0.011
-
Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol. 2003 Oct; 170(4 Pt 1):1141-5.
Score: 0.010
-
Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res. 2002 Nov 15; 62(22):6717-23.
Score: 0.010